On October 30, 2019 argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, reported that management will participate in several upcoming investor conferences in November (Press release, argenx, OCT 30, 2019, View Source [SID1234550052]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

2019 Wolfe Research Healthcare Conference. Company presentation on Wednesday, November 6, 2019 at 12:55 p.m. ET in New York.

28th Annual Credit Suisse Healthcare Conference. Management will participate in investor meetings on Wednesday, November 13, 2019 in Scottsdale, AZ.

Guggenheim Healthcare Talks | Idea Forum | Neuro / Immunology Day. Company presentation on Monday, November 18, 2019 at 3:15 p.m. ET in New York.

Stifel 2019 Healthcare Conference. Company presentation on Tuesday, November 19, 2019 at 10:55 a.m. ET in New York.

Live webcasts of each presentation will be available on the Company’s website at www.argenx.com. Replays of the webcasts will be available for 90 days following each presentation on the argenx website.